CXCR1 and neoplasm: Prior studies showed that monotherapy with CXCR1/2 inhibitor SX682 or with anti-PD1 ICB alone had no significant effect on tumor growth or on the survival rate, but combination treatment reduced tumor growth and improved survival [39,40].